Prognostic significance of plasma scatter factor/hepatocyte growth factor levels in patients with metastatic hormone-refractory prostate cancer: Results from cancer and leukemia group B 150005/9480
Prognostic significance of plasma scatter factor/hepatocyte growth factor levels in patients with metastatic hormone-refractory prostate cancer: Results from cancer and leukemia group B 150005/9480
复制标题
DOI：
10.3816/cgc.2006.n.006
复制
发表时间：
2006-03-01
影响因子：
3.2
通讯作者：
Kantoff, Philip W.
中科院分区：
文献类型：
--
作者：
Humphrey, Peter A.;Halabi, Susan;Kantoff, Philip W.
背景：散点因子，也称为肝细胞生长因子（SF/HGF），是一种多肽生长因子，被认为在前列腺癌的生长和扩散中起重要作用。患者和方法：采用固相酶联免疫吸附法对CALGB 9480中171例转移性激素难治性前列腺癌患者的预处理血浆样本中的散射因子/HGF水平进行定量分析。结果：采用Cox比例风险模型评估SF/HGF对预后的重要性，并对已建立的预后因素进行调整。SF/HGF中位数为991 pg/mL（范围为212-2733 pg/mL）。在单变量分析中，尽管血浆SF/HGF水平高于中位数与低于中位数没有达到统计学意义（P = 0.0862），但截断点bbb935 pg/mL与总生存期的显着降低相关（P = 0.0334）。SF/HGF水平为3935 pg/mL的患者中位生存期为15个月，而SF/HGF水平为5935 pg/mL的男性患者中位生存期为19个月。在多因素分析中，调整SF/HGF、前列腺特异性抗原、乳酸脱氢酶和工作状态后，只有血浆碱性磷酸酶与总生存率显著相关（风险比为1.7；95%可信区间为1.2-2.5;P = 0.0017）。结论：激素难治性前列腺癌患者血浆中SF/HGF水平升高与患者生存率降低相关。目前，SF/HGF水平在预测预后的多变量模型中似乎没有价值，但与生存率降低的关联表明SF/HGF可能是治疗的潜在目标。
Background: Scatter factor, also known as hepatocyte growth factor (SF/HGF), is a polypeptide growth factor thought to be important in the growth and spread of prostatic carcinoma. Patients and Methods: Scatter factor/HGF levels in pretreatment plasma samples from 171 men with metastatic hormone-refractory prostate cancer enrolled in CALGB 9480 were quantified by solid-phase, enzyme-linked immunosorbent assay. Results: The Cox proportional hazards model was used to assess the prognostic importance of SF/HGF with adjustment for established prognostic factors. Median SF/HGF was 991 pg/mL (range, 212-2733 pg/mL). In a univariate analysis, although plasma SF/HGF levels above versus below the median value did not reach statistical significance (P = 0.0862), the cutoff point of > 935 pg/mL was associated with a significant reduction in overall survival (P = 0.0334). Patients with SF/HGF levels > 935 pg/mL experienced a median survival of 15 months compared with 19 months for men with SF/HGF levels :5 935 pg/mL. In a multivariate analysis, adjusting for SF/HGF, prostatespecific antigen, lactate dehydrogenase, and performance status, only plasma alkaline phosphatase was significantly associated with overall survival (hazard ratio, 1.7; 95% confidence interval, 1.2-2.5; P = 0.0017). Conclusion: Higher plasma levels of SF/HGF in men with hormonerefractory prostate cancer are associated with a decreased patient survival. Currently, SF/HGF levels do not appear to be of value as a contributor to multivariate models for prediction of outcome, but the association with decreased survival suggests that SF/HGF might be a potential target for therapy.